Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Fibrosis, Liver
Type 2 Diabetes Mellitus in Obese
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Semaglutide
DRUG: Placebo

Sponsor

University of California, San Diego